Literature DB >> 25760729

DNA methylation of DKK3 modulates docetaxel chemoresistance in human nonsmall cell lung cancer cell.

Leilei Tao1, Guichun Huang, Yitian Chen, Longbang Chen.   

Abstract

Dickkopf-related protein 3 (DKK3) gene, as a tumor suppressor gene, has been discovered in various cancers, but its relationship with tumor chemoresistance is still unclear. In this study, this laboratory detected that DNA methylation contributes to the downregulation of DKK3 in docetaxel resistance of human lung cancer cells and its possible biochemical mechanism. DKK3 has been proved to be downregulated by hypermethylation in docetaxel-resistant lung cancer cells. Upregulation of DKK3 can reverse the chemoresistance of docetaxel-resistant cell lines in vitro by growth inhibition and enhancement of apoptosis. Conversely, downregulation of DKK3 could induce parental human lung cancer cells insensitivity to docetaxel by promoting proliferative capacity and inhibiting apoptosis of cancer cells. In addition, the authors observed that overexpression of DKK3 might decrease the expression of P-glycoprotein. All results suggested that epigenetic downregulation of DKK3 leads to docetaxel resistance in human nonsmall cell lung cancer (NSCLC) cells by increased expression of P-glycoprotein. DKK3 may reveal a novel molecular target for docetaxel resistance for NSCLC patients in the future.

Entities:  

Keywords:  DKK3; DNA methylation; NSCLC; chemoresistance; docetaxel

Mesh:

Substances:

Year:  2015        PMID: 25760729     DOI: 10.1089/cbr.2014.1797

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  9 in total

1.  Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.

Authors:  Marta Geretto; Alessandra Pulliero; Camillo Rosano; Dinara Zhabayeva; Rakhmet Bersimbaev; Alberto Izzotti
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

2.  Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.

Authors:  Stephanie N Dorman; Katherina Baranova; Joan H M Knoll; Brad L Urquhart; Gabriella Mariani; Maria Luisa Carcangiu; Peter K Rogan
Journal:  Mol Oncol       Date:  2015-08-22       Impact factor: 6.603

Review 3.  Autophagy-Dependent Secretion: Contribution to Tumor Progression.

Authors:  Tom G Keulers; Marco B E Schaaf; Kasper M A Rouschop
Journal:  Front Oncol       Date:  2016-11-25       Impact factor: 6.244

4.  GATA4 promotes hepatoblastoma cell proliferation by altering expression of miR125b and DKK3.

Authors:  Yihua Pei; Qin Yao; Sibo Yuan; Bozhen Xie; Yan Liu; Chunsheng Ye; Huiqin Zhuo
Journal:  Oncotarget       Date:  2016-11-22

5.  CRISPR-Mediated Reactivation of DKK3 Expression Attenuates TGF-β Signaling in Prostate Cancer.

Authors:  Hoda Kardooni; Estela Gonzalez-Gualda; Emmanouil Stylianakis; Sina Saffaran; Jonathan Waxman; Robert M Kypta
Journal:  Cancers (Basel)       Date:  2018-05-28       Impact factor: 6.639

Review 6.  Role of DNA Methylation in the Resistance to Therapy in Solid Tumors.

Authors:  Susana Romero-Garcia; Heriberto Prado-Garcia; Angeles Carlos-Reyes
Journal:  Front Oncol       Date:  2020-08-07       Impact factor: 5.738

7.  MiR-363-3p promotes prostate cancer tumor progression by targeting Dickkopf 3.

Authors:  Li-Zhe Xu; Jin-Zhuo Ning; Yuan Ruan; Fan Cheng
Journal:  J Clin Lab Anal       Date:  2022-03-18       Impact factor: 2.352

8.  Clinical and radiological characteristics of central pulmonary adenocarcinoma: a comparison with central squamous cell carcinoma and small cell lung cancer and the impact on treatment response.

Authors:  Zhe Wang; Minghuan Li; Yong Huang; Li Ma; Hui Zhu; Li Kong; Jinming Yu
Journal:  Onco Targets Ther       Date:  2018-05-04       Impact factor: 4.147

9.  pathCHEMO, a generalizable computational framework uncovers molecular pathways of chemoresistance in lung adenocarcinoma.

Authors:  Nusrat J Epsi; Sukanya Panja; Sharon R Pine; Antonina Mitrofanova
Journal:  Commun Biol       Date:  2019-09-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.